Our finding that KRAS-driven mechanisms maintain cellular growth and immunosuppression of both adaptive and innate immunity, highlights future therapeutic strategies that should consider a combination of KRAS cancer-targeting therapy with strategies targeting both T cells and myeloid cells. Here, KRAS is linked to cancer.